M-tron Industries, Inc. Reports Second Quarter 2026 Results
Revenue rose on stronger Elfabrio sales and a $25 million milestone payment from Chiesi, while Protalix reaffirmed its full-year 2026 outlook.
- Reporting Q2 2026 financial results, Protalix Biotherapeutics outlined an Elfabrio path for future market growth. Meanwhile, companies across various sectors reported their latest performance amid ongoing economic uncertainty.
- Damien Lamendola, Chief Executive Officer of Marpai, Inc. , reported progress in "revamping our cost structure" through AI-driven process improvements, despite a $4.6 million net loss. Many firms are working to streamline operations and cut costs.
- Totaling $209.7 million, Fossil Group, Inc. revenue grew. Additionally, Kruger Products Inc. achieved $550.9 million in revenue, driven by higher sales volume and lower pulp prices.
- Talon Metals Corp. announced board changes, with Board Member Victoria McMillan joining on August 13, 2026. Separately, Sera Prognostics, Inc. secured Illinois Medicaid coverage for its PreTRM test, impacting 50,000 annual births.
- Raising its full-year outlook based on recent performance, the firm continues focusing on long-term commercialization and efficiency. Management aims to drive future profitability through 2029 by executing its strategic directives and operational improvements.
37 Articles
37 Articles
Marpai Reports Second Quarter 2026 Financial Results
Successful turnaround leads to lower operating costs and improved gross margin; debt restructuring and subsequent financing strengthen capital structure TAMPA, Fla., Aug. 13, 2026 /PRNewswire/ — Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management (“PBM”) services, announced its financial and operational results for the three and si…
Idaho Strategic Reports Second Quarter 2026 Operating and Financial Performance
Highlighted by a 13.25% Increase in Revenue to $10,732,335 COEUR D’ALENE, Idaho — Idaho Strategic Resources, Inc. (NYSE American: IDR) (“IDR”, “Idaho Strategic” or the “Company”) today announced its consolidated operating and financial results for the second quarter ending June 30, 2026. Operating and financial results for the second quarter include: Operational Performance: Q2 2026 […]
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter. Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and…
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium